MedPath

Colesevelam

Generic Name
Colesevelam
Brand Names
Cholestagel, Lodalis, Welchol
Drug Type
Small Molecule
CAS Number
182815-43-6
Unique Ingredient Identifier
1XU104G55N
Background

Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol.

Indication

用于以胆固醇升高为主的高脂血症,当饮食和锻炼不能良好达到效果者,可单独使用或与他汀类合用。

Associated Conditions
Heterozygous Familial Hypercholesterolemia (HeFH), Hyperlipidemias, Type 2 Diabetes Mellitus, Primary Hyperlipidemia

WelChol® and Insulin in Treating Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Type 2 Diabetes
First Posted Date
2005-09-09
Last Posted Date
2012-01-18
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
260
Registration Number
NCT00151749

Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Type 2 Diabetes
First Posted Date
2005-09-09
Last Posted Date
2008-01-09
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
780
Registration Number
NCT00151762

Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes

Phase 2
Completed
Conditions
Type 2 Diabetes
Interventions
First Posted Date
2005-09-07
Last Posted Date
2014-04-02
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
36
Registration Number
NCT00147745
Locations
🇺🇸

San Diego VMC, San Diego, California, United States

WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Type 2 Diabetes
First Posted Date
2005-09-07
Last Posted Date
2012-01-18
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
400
Registration Number
NCT00147758

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Type 2 Diabetes
First Posted Date
2005-09-07
Last Posted Date
2012-01-18
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
300
Registration Number
NCT00147719
Locations
🇺🇸

CRO, Jonesboro, Arkansas, United States

Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol

Phase 4
Completed
Conditions
Hypercholesterolemia
Interventions
First Posted Date
2005-09-05
Last Posted Date
2010-04-15
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
194
Registration Number
NCT00145574
© Copyright 2025. All Rights Reserved by MedPath